AVITA Medical

AVITA Medical

AVITA Medical operates as a publicly traded commercial-stage regenerative medicine company. The firm secured FDA premarket approval for its RECELL Autologous Cell Harvesting Device, designed to prepare a spray-on suspension of a patient's own skin cells for the treatment of severe burns. Corbett has steered the organization since 2019, focusing commercialization on U.S. burn centers. The core technology centers on enzymatic disaggregation of a small split-thickness skin sample into a cellular suspension that can treat a wound up to 80 times the size of the donor site. The platform reduces donor-site morbidity and the number of surgical procedures for patients with large total body surface area burns. Key milestones include BARDA's multi-year partnership to expand RECELL's label for mass-casualty preparedness. The company maintains a direct sales force targeting Level 1 burn centers and has expanded into pediatric labelling and treatment of full-thickness burns. AVITA Medical is listed on both the Australian Securities Exchange and the Nasdaq. The company has pursued an adjacent launch into vitiligo treatment and soft-tissue reconstruction, diversifying beyond acute burn care. In recent periods, the organization has reported sequential quarter-over-quarter growth in commercial accounts, supported by increased procedural volumes at existing hospital customers. The firm's structural profile is that of a single-product platform scaling through regulatory pathway expansion. Unlike private-equity-backed competitors, AVITA operates with public-market capital and a narrow clinical focus, which creates a concentrated risk and reward profile tied directly to the adoption of RECELL across burn surgery protocols.